Nanovibronix, inc. (NAOV)
Income statement / TTM
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Revenues

-

498

451

320

-

333

344

264

239

218

214

224

229

219

198

175

147

284

269

294

203

0

0

0

Cost of revenues

249

171

163

162

158

155

131

94

88

68

73

77

88

90

73

66

49

70

85

0

-

0

0

-

Cost of revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Gross profit

281

327

288

158

160

178

213

170

151

150

141

147

141

129

125

109

98

194

154

169

110

0

0

0

Operating expenses:
Research and development

514

587

629

630

614

627

666

679

693

610

611

620

584

550

476

418

399

628

642

616

431

0

0

0

Selling and marketing

1,096

1,161

1,278

1,304

1,212

1,027

791

600

465

432

443

463

514

561

514

413

377

368

437

479

301

0

0

0

General and administrative

3,822

3,853

4,188

3,960

2,637

2,482

2,001

1,971

2,084

2,023

1,934

1,707

1,359

953

863

865

746

754

811

763

589

0

0

0

Total operating expenses

5,432

5,601

6,095

5,894

4,463

4,135

3,457

3,249

3,242

3,066

2,989

2,791

2,457

2,064

1,853

1,696

1,522

1,727

1,867

1,835

1,321

0

0

0

Loss from operations

-5,151

-5,274

-5,807

-5,736

-4,303

-3,957

-3,244

-3,079

-3,091

-2,916

-2,848

-2,644

-2,316

-1,935

-1,728

-1,587

-1,424

-1,533

-1,713

-1,666

-1,211

0

0

0

Financial income (expense), net

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of derivative liabilities

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on extinguishment of derivative liability

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrant modification expense

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Financial expense, net (Note 12)

-

-

-

-

-

-

-

-

1,836

1,407

484

450

398

528

1,159

1,129

1,432

1,359

976

0

-

0

0

-

Financial expense, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Loss before taxes

-5,811

-5,938

-6,458

-6,171

-4,281

-4,559

-4,814

-4,838

-4,927

-4,323

-3,332

-3,094

-2,714

-2,463

-2,887

-2,716

-2,856

-2,856

-2,600

-2,739

-2,598

0

0

0

Income tax benefit

-17

-140

-131

-127

-127

38

38

39

38

122

120

119

117

29

38

33

28

47

30

35

49

0

0

0

Net loss

-5,794

-5,798

-6,327

-6,044

-4,154

-4,597

-4,852

-4,877

-4,965

-4,445

-3,452

-3,213

-2,831

-2,492

-2,925

-2,749

-2,884

-2,903

-2,630

-2,774

-2,647

0

0

0

Deemed dividend related to extension of February 2015 warrants to Common stock in January 2017

-

-

-

-

-

-

-

-

841

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

Total comprehensive loss attributable to holders of Common Stock

-

-

-

-

-

-

-

-

-

-5,286

-4,293

-4,054

-2,831

-2,492

-2,925

-2,749

-2,884

-2,903

-2,630

-2,774

-2,647

0

0

0

Basic and diluted net loss available for holders of common stock, Series C Preferred Stock and Series D Preferred Stock

-0.15

-0.12

-0.16

-0.40

-0.18

-0.21

-0.13

-0.12

-0.27

-0.35

-0.18

-0.37

-0.25

-0.13

-0.13

-0.11

1.75

-0.23

-0.10

-2.24

-5.17

-4.94

-3.73

-3.24

Weighted average common shares outstanding: Basic and diluted

7,261

7,054

6,788

6,652

6,506

6,438

6,429

6,419

6,094

4,583

4,594

4,583

4,584

4,582

4,574

4,572

5,073

4,562

4,227

281

-

155

155

-

Weighted average number of shares of Common stock used in computing basic and diluted net loss per share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

155